BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
BeyondSpring Inc. (NASDAQ: BYSI) announces upcoming presentations showcasing its lead anti-cancer asset, Plinabulin, at two major oncology conferences. At the 2024 World Conference on Lung Cancer on September 9, an oral presentation will reveal final efficacy data of Plinabulin and docetaxel combination vs. docetaxel from the Dublin-3 phase 3 study in EGFR wild-type 2L/3L non-small cell lung cancer (NSCLC).
Additionally, at the ESMO Congress 2024 on September 14, two poster presentations will cover the Dublin-3 study safety outcome and the 303 Study, an investigator-initiated study supported by Merck in 2L/3L NSCLC patients who failed PD-1/PD-L1 inhibitors. These presentations highlight BeyondSpring's ongoing efforts in developing innovative cancer therapies, particularly for lung cancer patients.
BeyondSpring Inc. (NASDAQ: BYSI) annuncia prossime presentazioni che metteranno in risalto il suo principale asset anticancro, Plinabulin, in due importanti conferenze oncologiche. Alla 2024 World Conference on Lung Cancer del 9 settembre, una presentazione orale svelerà i dati finali di efficacia della combinazione di Plinabulin e docetaxel rispetto al solo docetaxel nello studio di fase 3 Dublin-3 in pazienti con cancro polmonare non a piccole cellule (NSCLC) con mutazione EGFR wild-type 2L/3L.
Inoltre, al ESMO Congress 2024 del 14 settembre, due presentazioni poster tratteranno i risultati di sicurezza dello studio Dublin-3 e lo Studio 303, uno studio iniziato da investigatori supportato da Merck in pazienti NSCLC 2L/3L che hanno fallito gli inibitori PD-1/PD-L1. Queste presentazioni evidenziano gli sforzi continui di BeyondSpring nello sviluppo di terapie innovative per il cancro, in particolare per i pazienti affetti da cancro al polmone.
BeyondSpring Inc. (NASDAQ: BYSI) anuncia próximas presentaciones que destacarán su principal activo anticancerígeno, Plinabulin, en dos importantes conferencias de oncología. En la 2024 World Conference on Lung Cancer el 9 de septiembre, una presentación oral revelará los datos finales de eficacia de la combinación de Plinabulin y docetaxel frente a docetaxel solo en el estudio de fase 3 Dublin-3 en pacientes con cáncer de pulmón no microcítico (NSCLC) EGFR wild-type 2L/3L.
Además, en el ESMO Congress 2024 el 14 de septiembre, dos presentaciones en cartel cubrirán los resultados de seguridad del estudio Dublin-3 y el Estudio 303, un estudio iniciado por investigadores respaldado por Merck en pacientes de NSCLC 2L/3L que fallaron en los inhibidores de PD-1/PD-L1. Estas presentaciones destacan los esfuerzos continuos de BeyondSpring en el desarrollo de terapias innovadoras contra el cáncer, particularmente para pacientes con cáncer de pulmón.
BeyondSpring Inc. (NASDAQ: BYSI)는 주요 항암 자산인 Plinabulin을 선보이는 두 개의 주요 종양학 회의에서 발표를 진행할 예정이라고 발표했습니다. 2024 세계 폐암 회의가 9월 9일에 열리고, 여기서 구두 발표를 통해 Dublin-3 3상 연구에서 EGFR 와일드타입 2L/3L 비소세포 폐암(NSCLC) 환자를 위한 Plinabulin과 도세탁셀 조합의 최종 효능 데이터를 공개할 예정입니다.
또한 9월 14일 ESMO Congress 2024에서 두 개의 포스터 발표가 Dublin-3 연구의 안전성 결과와 Merck의 지원을 받는 조사자 주도 연구인 303 연구를 다룰 것입니다. 이 발표들은 BeyondSpring이 폐암 환자를 위한 혁신적인 암 치료 개발에 지속적으로 노력하고 있음을 강조합니다.
BeyondSpring Inc. (NASDAQ: BYSI) annonce des présentations à venir mettant en avant son principal actif anticancéreux, Plinabulin, lors de deux grandes conférences en oncologie. Lors de la 2024 World Conference on Lung Cancer le 9 septembre, une présentation orale révèlera les données finales d'efficacité de la combinaison Plinabulin et docétaxel par rapport au docétaxel seul, issues de l'étude de phase 3 Dublin-3 chez des patients atteints de cancer du poumon non à petites cellules (NSCLC) avec mutation EGFR wild-type 2L/3L.
De plus, lors du ESMO Congress 2024 le 14 septembre, deux présentations sous forme d'affiches couvriront les résultats de sécurité de l'étude Dublin-3 et l'étude 303, une étude initiée par des investigateurs soutenue par Merck chez des patients NSCLC 2L/3L ayant échoué à des inhibiteurs PD-1/PD-L1. Ces présentations soulignent les efforts continus de BeyondSpring dans le développement de thérapies anticancéreuses innovantes, en particulier pour les patients atteints de cancer du poumon.
BeyondSpring Inc. (NASDAQ: BYSI) kündigt bevorstehende Präsentationen an, die ihr führendes Anti-Krebs-Mittel, Plinabulin, auf zwei bedeutenden Onkologie-Konferenzen vorstellen werden. Auf der 2024 World Conference on Lung Cancer am 9. September wird eine mündliche Präsentation endgültige Wirksamkeitsdaten der Kombination von Plinabulin und Docetaxel im Vergleich zu Docetaxel allein aus der Dublin-3 Phase 3-Studie bei EGFR Wildtyp 2L/3L nicht-kleinzelligem Lungenkrebs (NSCLC) enthüllen.
Zusätzlich werden beim ESMO Congress 2024 am 14. September zwei Posterpräsentationen die Sicherheitsdaten der Dublin-3-Studie und die Studie 303, eine vom Untersucher initiierte Studie, die von Merck unterstützt wird, bei 2L/3L NSCLC-Patienten, die gegen PD-1/PD-L1-Inhibitoren versagt haben, behandeln. Diese Präsentationen unterstreichen die fortlaufenden Bemühungen von BeyondSpring, innovative Krebstherapien, insbesondere für Patienten mit Lungenkrebs, zu entwickeln.
- Oral presentation of final efficacy data from Dublin-3 phase 3 study at World Conference on Lung Cancer
- Two poster presentations at ESMO Congress 2024 showcasing Plinabulin's potential in NSCLC
- Collaboration with Merck on investigator-initiated study (303 Study)
- None.
FLORHAM PARK, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announces that it will have an oral presentation on the final efficacy data of Plinabulin and docetaxel combination vs. docetaxel from Dublin-3 phase 3 study in EGFR wild-type 2L/3L non-small cell lung cancer (NSCLC) at the 2024 World Conference on Lung Cancer, on September 9, 2024 in San Diego, CA, and two poster presentations on Dublin-3 study safety outcome and 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) in 2L/3L NSCLC who failed PD-1/PD-L1 inhibitors at European Society for Medical Oncology (ESMO) Congress 2024, on September 14, 2024 in Barcelona, Spain.
Presentation details are as follows:
2024 World Conference on Lung Cancer
Oral (OA08.04): Plinabulin/Docetaxel vs. Docetaxel in 2L/3L NSCLC after Platinum Regimens (DUBLIN-3): A Phase 3 Randomized Controlled Trial
- Presenter: Dr. Trevor M. Feinstein, Principal investigator for Dublin-3 study, Piedmont Cancer Institute, Atlanta, GA, USA
- Presentation Time: Monday, September 9, 2024, at 10:57AM to 11:07AM PDT
- Session: OA08. The New Generation of Cytotoxics
ESMO Congress 2024
Poster (1358P): Plinabulin/Docetaxel Versus Docetaxel in Survival Benefits of 2L/3L EGFR Wild-Type NSCLC after Platinum Regimens (DUBLIN-3): a Randomized Phase 3 Trial
- Presenter: Dr. Trevor M. Feinstein
- Presentation Time: Saturday, September 14, 2024, at 9AM to 6:30PM CEST
- Location: Hall 3, Av. Joan Carles I, 64
08908 L’hospitalet de Llobregat
Barcelona, Spain
- Session: NSCLC, metastatic
Poster (1330P): Phase 2 Study of Pembrolizumab (Pemb) plus Plinabulin (Plin) and Docetaxel (Doc) for Patients (pts) with Metastatic NSCLC after Failure on First-line Immune Checkpoint Inhibitor Alone or Combination Therapy: Initial Efficacy and Safety Results on Immune Re-sensitization
- Presenter: Dr. Yan Xu, Investigator, Peking Union Medical College Hospital, Beijing, China
- Presentation Time: Saturday, September 14, 2024, at 9AM to 6:30PM CEST
- Location: Hall 3, Av. Joan Carles I, 64
08908 L’hospitalet de Llobregat
Barcelona, Spain
- Session: NSCLC, metastatic
About BeyondSpring
BeyondSpring is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, a potent inducer of dendritic cell maturation, in late-stage clinical development as a direct anti-cancer agent in NSCLC and a variety of cancer indications. BeyondSpring’s pipeline also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring is an equity owner of SEED Therapeutics, Inc which is a pioneer in Target Protein Degradation technology and its application in innovative drug development. Learn more by visiting https://beyondspringpharma.com.
About Dublin-3 Study
Dublin-3 NSCLC was a global Phase 3 randomized, controlled clinical trial comparing the combination of Plinabulin and docetaxel to an active control arm of docetaxel alone (1:1 randomization) in second- and third-line NSCLC patients who had failed platinum doublet therapies, and who were Epidermal Growth Factor Receptor (EGFR) wild-type. Docetaxel was given on Day 1 in both arms at 75 mg/m2 in each 21-day cycle. Plinabulin was given on Day 1, one hour after docetaxel, and on Day 8, both at 30 mg/m2 in each cycle. The primary endpoint for the study was overall survival, and secondary endpoints were Progression Free Survival (PFS), Overall Response Rate (ORR), Duration of Response (DoR), Grade 4 neutropenia and Quality of Life.
About 303 Study
Study 303 is an open-label, single-arm Phase 2 Study of Plinabulin plus docetaxel and pembrolizumab for previously treated patients with metastatic NSCLC and progressive disease after anti-PD-(L)1 inhibitor alone or in combination with platinum-doublet chemotherapy. This study evaluates the efficacy and safety of this triple combination and is being conducted at Peking Union Medical College Hospital, Beijing, China with Dr. Mengzhao Wang, Chief of the Department of Respiratory and Critical Care Medicine, as the principal investigator and with Merck. Patients enrolled are receiving the following interventional treatments. The primary endpoint is investigator-based ORR (RECIST 1.1). The secondary endpoints include PFS, OS, DoR, and safety. The study intends to enroll 47 patients with a formal interim analysis of 19 patients enrolled. The regimen includes Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1, Docetaxel 75 mg/m2 IV Q3W on Day 1 and Plinabulin 30mg/m2 IV Q3W on Day 1 in a 21-day cycle. The study is funded by Merck’s Investigator Studies Program with provision of study drug and financial support.
Investor Contact:
IR@beyondspringpharma.com
Media Contact:
PR@beyondspringpharma.com
FAQ
What is BeyondSpring's lead anti-cancer asset being presented at the 2024 World Conference on Lung Cancer?
When and where will BeyondSpring (BYSI) present the final efficacy data of the Dublin-3 phase 3 study?
What studies will BeyondSpring (BYSI) present at the ESMO Congress 2024?
Who is presenting BeyondSpring's (BYSI) Dublin-3 study results at the 2024 World Conference on Lung Cancer?
